Pharmanutra S.p.A. (FRA:761)

Market Cap	839.74M +83.3%
Revenue (ttm)	138.94M +17.0%
Net Income	21.02M +28.1%
EPS	2.20 +28.8%
Shares Out	n/a
PE Ratio	39.95
Forward PE	34.31
Dividend	1.20 (1.39%)
Ex-Dividend Date	May 4, 2026

Volume	n/a
Open	85.90
Previous Close	86.70
Day's Range	85.90 - 85.90
52-Week Range	38.55 - 94.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 8, 2026

About Pharmanutra

Pharmanutra S.p.A., a nutraceutical company, engages in the research and development and marketing of food supplements and medical devices in Europe, the Middle East, Far East, North America, South America, and internationally. The company produces and distributes raw materials and active ingredients for the food, pharmaceutical, and dietary supplement industries. It offers Sucrosomial, a delivery system that optimises nutrient transport and absorption for minimising gastrointestinal side effects; and Cetylated Fatty Acids, a formulation for mu...

• Industry: Pharmaceutical Preparations
• Founded: 2000
• Employees: 140
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 761

Financial Performance

In 2025, Pharmanutra's revenue was 132.16 million, an increase of 13.78% compared to the previous year's 116.15 million. Earnings were 20.00 million, an increase of 20.44%.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Jun 27, 2026

Data Sources Report a data error